Multicentric study of efficacy and safety of growth hormone use in growth hormone deficient children in India |
| |
Authors: | V V Khadilkar A V Khadilkar M Nandy G B Maskati |
| |
Institution: | (1) Medical Services and Product Development, LG Life Sciences India Pvt. Ltd., Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital, Pune, India;(2) Consultant Paediatric Endocrinologist, Hirabai Cowasji Jehangir Medical Research Institute, Jehangir Hospital, 32, Sassoon Road, Pune, 411001, India |
| |
Abstract: | Growth Hormone being very expensive in India data on use of recombinant human growth hormone (rhGH) is scarce. The authors
studied the effect and safety of one year of therapy with rhGH on growth velocity and predicted final height in Indian patients
with growth hormone deficiency (GHD). A multicentric, prospective, open trial with rhGH was performed on 15 patients. Patients
received rhGH in a dose of 0.7 IU (0.23 mg)/Kg/week. The mean pretreatment height was 111.2cms {SD 12.4}, height velocity
was 3.1 cms per year {1.2} and predicted height was 146.5 cms {10.4} at a mean age of 12.0 (2.8). At the end of therapy mean
height was 123.4 {11.9}, height velocity was 12.1 cms per year {2.8} and the predicted height was 153.0 cm {9.4}. The increase
in predicted height was thus 6.5cm (4.2). The increment in height velocity with growth hormone therapy was statistically significant
(p value= 0.001). The present study shows that children with growth hormone deficiency in India also benefit from therapy
with rhGH even when treatment is started late as compared to the published Western data and there is a potential for increased
final height. |
| |
Keywords: | Growth hormone Height velocity Growth hormone deficiency |
本文献已被 PubMed SpringerLink 等数据库收录! |
|